US Broker Ratings

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating a 28.75% Potential Upside in the Biotech Sector

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a noteworthy player in the biotechnology sector, captivating investor interest with its robust pipeline and compelling financial metrics. As of recent trading, REGN..

argenx SE (ARGX) Stock Analysis: A Biotech Powerhouse with 18.35% Upside Potential

argenx SE (ARGX), a frontrunner in the biotechnology sector, is capturing the attention of investors with its robust revenue growth and promising pipeline of therapies targeting autoimmune diseases. Based in..

Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Potential Upside and Strategic Positioning in Medical Devices

Smith & Nephew SNATS, Inc. (NYSE: SNN) is a noteworthy player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $13.49 billion, this UK-based..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Exploring a Potential 14.72% Upside in the Medical Devices Sector

Bio-Rad Laboratories, Inc. (NYSE: BIO), a prominent player in the healthcare sector, is making waves in the medical devices industry with its recent stock price movements and promising analyst ratings...

AstraZeneca PLC (AZN) Stock Analysis: A Robust 17.12% Potential Upside Captures Investor Attention

AstraZeneca PLC (AZN) stands as a formidable player in the healthcare sector, particularly within the drug manufacturing industry. Based in Cambridge, United Kingdom, the company boasts a substantial market capitalization..

Illumina, Inc. (ILMN) Stock Analysis: Navigating 20% Potential Upside Amidst Market Volatility

As the healthcare sector continues to be a focal point for investors, Illumina, Inc. (NASDAQ: ILMN) stands out as a key player in the diagnostics and research industry. Despite recent..

Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 22.06% Potential Upside Amidst Dividend Opportunities

Pfizer, Inc. (NYSE: PFE), a stalwart in the healthcare sector, has long been a powerhouse in the drug manufacturing industry. With a market capitalization of $133.55 billion, Pfizer is a..

Exelixis, Inc. (EXEL) Stock Analysis: Exploring a 21% Potential Upside in the Biotechnology Sector

Exelixis, Inc. (NASDAQ: EXEL), a leading player in the biotechnology sector, stands out with a promising potential upside of 21.06%, capturing the attention of individual investors seeking growth opportunities in..

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Unlocking a 61% Potential Upside

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a prominent player in the biotechnology sector, is capturing investor attention with its compelling growth prospects and robust pipeline of innovative treatments. Headquartered in Dublin,..

West Pharmaceutical Services, I (WST) Stock Analysis: Unpacking a 32% Upside Potential

For investors eyeing opportunities in the healthcare sector, West Pharmaceutical Services, Inc. (NYSE: WST) presents a compelling case. With a robust market cap of $17.2 billion and an influential presence..

Gilead Sciences, Inc. (GILD) Stock Analysis: Navigating Growth Amidst a Challenging Market Environment

Gilead Sciences, Inc. (NASDAQ: GILD), a stalwart in the biopharmaceutical space, continues to captivate investor attention with its robust product portfolio and strategic collaborations. With a market capitalization of $140.79..

Molina Healthcare Inc (MOH) Stock Analysis: Assessing a Compelling 30% Upside Potential

Molina Healthcare Inc (NYSE: MOH) is a prominent player in the healthcare sector, specifically within the healthcare plans industry. This Long Beach, California-based company focuses on providing managed healthcare services..

Chemed Corp (CHE) Investor Outlook: Analyzing a 35.75% Potential Upside with Robust Free Cash Flow

Chemed Corp (NYSE: CHE), a major player in the healthcare sector, operates through its two main segments, VITAS and Roto-Rooter. Known for its hospice and palliative care services, Chemed is..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Balancing Potential Upside with Strategic R&D Investments

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a powerhouse within the biotechnology sphere, recognized for its groundbreaking therapies in treating cystic fibrosis (CF). With a market capitalization of $118.67 billion,..

Royalty Pharma plc (RPRX) Stock Analysis: A Healthcare Giant with 13.58% Potential Upside

Royalty Pharma plc (NASDAQ: RPRX), a formidable player in the biotechnology sector, is drawing investor attention with its robust market presence and promising growth potential. With a current market capitalization..

Neurocrine Biosciences, Inc. (NBIX) Rating Update: Exploring a 30% Potential Upside

Neurocrine Biosciences, Inc. (NBIX) is drawing considerable attention in the healthcare sector, particularly among investors focused on drug manufacturers specializing in both specialty and generic products. With a market capitalization..

Viatris Inc. (VTRS) Stock Analysis: Exploring the 26.48% Potential Upside Amidst Financial Challenges

Viatris Inc. (NASDAQ: VTRS), a prominent player in the healthcare sector specializing in both specialty and generic drug manufacturing, presents a curious case for investors. Despite facing significant financial headwinds,..

Labcorp Holdings Inc. (LH) Stock Analysis: Unlocking 11.53% Potential Upside with Strong Buy Ratings

Labcorp Holdings Inc. (NYSE: LH) is a leading player in the healthcare sector, specifically in the diagnostics and research industry. Headquartered in Burlington, North Carolina, Labcorp provides a comprehensive range..

Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield

Bristol-Myers Squibb Company (NYSE: BMY), a stalwart in the healthcare sector and a prominent player in the global biopharmaceutical arena, presents an intriguing investment case. With a market capitalization of..

Merck & Company, Inc. (MRK) Stock Analysis: High Dividend Yield and a 26.64% Potential Upside

Merck & Company, Inc. (NYSE: MRK) stands as a formidable player in the healthcare sector, renowned for its extensive portfolio of pharmaceuticals and animal health products. As a major entity..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds